CSI Market
Sign In | Register

Definium Therapeutics Inc (DFTX) Annual Income Statement

Annual · GAAP · USD millions
Access DFTX quarterly income statements →
From Definium Therapeutics Inc through Dec 31 2020, changes in Dec 31 2025's revenue and cost structure provide insight into profitability trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
2025 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2020)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing48.64
Research and Development Expense117.67
Other Operating Expense / -Income0.00
Unusual Expense / Income0.00
Total operating costs including COS166.31
Operating income / -loss-166.31
Interest Expense5.48
Net Interest Expense / -Income5.48
Extinguishment of Debt0.00
Investment Income, Interest and Dividend-10.96
Foreign Currency Transaction Gain (Loss), before Tax-0.13
Other loss / -income0.91
Total costs & expenses183.79
Income & Taxes
Income / -loss before income taxes-183.79
Income after income taxes-183.79
Income / -loss from continuing operations-183.79
Net income / -loss-183.79
Income / -loss to shareholder-183.79
EBIT-178.31
EBITD-178.31
EBITDA-178.31
Earnings Per Share
Basic EPS (excl. extra items)-2.06
Extraordinary items0.00
Basic Net EPS-2.06
Basic shares outstanding (Mill. of Units)89.33
Diluted Net EPS-2.06
Diluted average shares (Mill. of Units)89.33
4 historic quarters locked

Sign in to unlock the full Definium Therapeutics Inc income statement history.

Sign In Create Free Account

About Definium Therapeutics Inc Annual Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-K filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-K filings
  • Filed with the SEC: February 26, 2026
  • Original filing: dftx-20251231.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.